CV Date	16/06/2025

Part A. PERSONAL INFORMATION

First Name	Jose Luis		
Family Name	Sardina Ortega		
Sex	Not Specified	Date of Birth	
ID number Social Security, Passport			
URL Web			
Email Address			
Open Researcher and Contributor ID (ORCID)	0000-0002-8493-3937		

A.1. Current position

Job Title	Group Leader		
Starting date	2019		
Institution	Josep Carreras Leukaemia Research Institute		
Department / Centre			
Country		Phone Number	
Keywords	240000 - Life Science		

A.2. Previous positions (Research Career breaks included)

Period	Job Title / Name of Employer / Country
2018 - 2019	Staff Scientist / Centre for Genomic Regulation / Spain
2012 - 2018	Postdoctoral Researcher / Centre for Genomic Regulation / Spain
2011 - 2012	Postdoctoral Researcher / Consejo Superior de Investigaciones Científicas / Spain
2010 - 2010	Research Personnel / University of Salamanca / Spain
2006 - 2010	PhD Student / University of Salamanca / Spain

A.3. Education

Degree/Master/PhD	University / Country	Year
PhD in Biology	University of Salamanca / Spain	2010
MPhil Theses in Biochemistry	University of Salamanca / Spain	2008
Degree in Biochemistry	University of Salamanca / Spain	2006
Degree in Biology	University of Salamanca / Spain	2005

Part B. CV SUMMARY

Part C. RELEVANT ACCOMPLISHMENTS

C.1. Most important publications in national or international peer-reviewed journals, books and conferences

AC: corresponding author. (nº x / nº y): position / total authors. If applicable, indicate the number of citations

1 **Scientific paper**. (1/17) J.L. Sardina (AC); S. Collombet; T.V. Tian; et al; T. Graf. 2018. Transcription Factors Drive Tet2-Mediated Enhancer Demethylation to Reprogram Cell Fate. Cell Stem Cell. Cell Press. 23-5, pp.727-741. ISSN 19345909.

2 **Scientific paper**. Bruno Di Stefano; Samuel Collombet; J.S Jakobsen; et al; T. Graf; (5/14) J.L Sardina. 2016. C/EBP? creates elite cells for iPSC reprogramming by upregulating Klf4 and increasing the levels of Lsd1 and Brd4. NAT CELL BIOL. Nature publishing group. 18-4, pp.371-381.

3 **Scientific paper**. (1/20) Clara Bueno*; Jose Luis Sardina*; Bruno Di Stefano; et al; P. Menendez. 2016. Reprogramming human B cells into induced pluripotent stem cells and its enhancement by C/EBP?. Leukemia. Nature publishing group. 30-3, pp.674-682. https://doi.org/10.1038/leu.2015.294

4 **Scientific paper**. JL Sardina; G López Ruano; R Prieto Bermejo; et al; A Hernández Hernández. 2014. PTPN13 regulates cellular signalling and ?-catenin function during megakaryocytic differentiation. BBA-MOL CELL RES. Elsevier. 1843-12, pp.2886-2899.

5 **Scientific paper**. Bruno Di Stefano; José Luis Sardina Ortega; Chris Van Ovelen; et al; Thomas Graf. 2014. C/EBP? poises B cells for rapid reprogramming into induced pluripotent stem cells. Nature. Nature Publishing Group. 506, pp.235-239.

6 **Scientific paper**. J.L. Sardina; G. Lopez-Ruano; L.I. Sanchez-Abarca; et al; A. Hernandez-Hernandez. 2010. p22phox-dependent NADPH oxidase activity is required for megakaryocytic differentiation. CELL DEATH DIFFER. 17-12, pp.1842-1854.

7 **Scientific paper**. B. Lopez-Millan; A. Rubio-Gayarre; M. Vinyoles; et al; C. Bueno; (13/29) J.L. Sardina. 2024. NG2 is a target gene of MLL-AF4 and underlies glucocorticoid resistance in MLLr B-ALL by regulating NR3C1 expression. Blood. American Society of Hematology. 144-19, pp.2002-2017. https://doi.org/10.1182/blood.2023022050

8 **Scientific paper**. A. Gamez-Garcia; M. Espinosa-Alcantud; A. Bueno-Costa; et al; A. Vaquero; (16/20) J.L. Sardina. 2024. A SIRT7-dependent acetylation switch regulates early B cell differentiation and lineage commitment through Pax5. Nature Immunology. Nature Publishing Group. 25-12, pp.2308-2319. https://doi.org/10.1038/s41590-024-01995-7

9 **Scientific paper**. K. Kodali; L. Proetti; G. Valcárcel; et al; B. Di Stefano; (30/32) J.L. Sardina (AC). 2024. RNA sequestration in P-bodies sustains myeloid leukaemia. Nature Cell Biology. Nature Publishing Group. 26-10, pp.1745-1758. https://doi.org/10.1038/s41556-024-01489-6

10 **Scientific paper**. M. Barrero; A. Lazarenkov; E. Blanco; et al; B. Payer; (9/10) J.L. Sardina. 2024. The interferon γ pathway enhances pluripotency and X-chromosome reactivation in iPSC reprogramming. Science Advances. American Association for the Advancement of Science. 10-32, pp.eadj8862. https://doi.org/10.1126/sciadv.adj8862

11 **Scientific paper**. F. Serra; A. Nieto-Aliseda; L. Fanlo-Escudero; et al; B.M. Javierre; (14/16) J.L. Sardina. 2024. p53 rapidly restructures 3D chromatin organization to trigger a transcriptional response. Nature Communications. Nature Publishing Group. 15-1. https://doi.org/10.1038/s41467-024-46666-1

12 **Scientific paper**. O. Morante-Palacios; G. Godoy-Tena; J. Calafell-Segura; L. Ciudad; E.M. Martínez-Cáceres; (6/7) J.L. Sardina; E. Ballestar. 2022. Vitamin C triggers NF-κB-driven epigenomic reprogramming and enhanced immunogenic responses of dendritic cells. Nucleic Acids Research. Oxford Academic. 50-19, pp.10981-10994. https://doi.org/10.1093/nar/gkac941

13 **Scientific paper**. A. Lazarenkov; (2/2) J.L. Sardina (AC). 2022. Dissecting TET2 Regulatory Networks in Blood Differentiation and Cancer. Cancers (Basel). MDPI. 14-3, pp.830-830. https://doi.org/10.3390/cancers14030830

14 **Scientific paper**. S. Collombet; (2/8) C. van Oevelen*; J.L. Sardina*; W. Abou Jaoudé; B. Di Stefano; Thomas-Chollier; T. Graf; D. Thieffry. 2017. Logical modeling of lymphoid and myeloid cell specification and transdifferentiation. P NATL ACAD SCI USA. 114-23, pp.5792-5799. https://doi.org/doi: 10.1073/pnas.1610622114.

15 G. Valcárcel; A.V. Lopez-Rubio; A. Lazarenkov; C. Berenguer; J. Calafell-Segura; J. Rodrigiuez-Ubreva; E. Ballestar; (8/8) J.L. Sardina (AC). 2024. Modulating immune cell fate and inflammation through CRISPR-mediated DNA methylation editing. BioRxiv. https://doi.org/10.1101/2024.07.10.599183

C.2. Conferences and meetings

1 Modulating Immune Cell Fate and Inflammation through CRISPR-mediated Epigenome Editing. CLEPIC 2025. isMoCLEP. 2025. Italy. Participatory - oral communication. Conference.
2 J.L. Sardina. The interplay between RNA sequestration in P-bodies and chromatin architecture sustains myeloid leukemia. XIII Annual Chromatin and Epigenetics symposium. Catalan Society of Biology (SCB). 2023. Participatory - invited/keynote talk.
3 J.L. Sardina. Transcription factors drive TET2-mediated enhancer demethylation during immune cell fate decisions. Cancer Epigenetics: Principles, Applications and single-cell resolution. INTERCEPT-MDS. 2022. Greece. Participatory - invited/keynote talk. Conference.
4 J.L. Sardina; S. Collombet; T.V. Tian; et al; T. Graf. Transcription Factors Drive Tet2-Mediated Enhancer Demethylation to Reprogram Cell Fate. From Epigenome towards Epitranscriptome in Cell Fate Choice. EMBO. 2018. Italy. Participatory - oral communication. Conference.
5 J.L. Sardina; S. Collombet; T.V. Tian; et al; T. Graf. Transcription Factors Drive Tet2-Mediated Enhancer Demethylation to Reprogram Cell Fate. 41 Congreso de la Sociedad Española de Bioquímica y Biología Molecular. Sociedad Española de Bioquímica y Biología Molecular. 2018. Spain. Participatory - oral communication.
6 J.L. Sardina; S. Collombet; A. Gomez; et al; T. Graf. DNA hydroxy-methylation and methylation dynamics during rapid reprogramming of somatic cells into iPSCs.. Premeeting EHA. European Hematology Association. 2017. Spain. Participatory - oral communication. Conference.
7 J.L. Sardina; A. Gomez; S. Collombet; et al; T. Graf. Rapid demethylation of pluripotency gene regulatory regions during reprogramming of C/EBP?-primed B cells into iPSCs. XXXIX Congreso de la Sociedad Española de Bioquímica y Biología Molecular. Sociedad Española de Bioquímica y Biología Molecular. 2016. Spain. Participatory - oral communication. Conference.

C.3. Research projects and contracts

1 **Project**. 101119927, Storming Immune Monogenic Conditions through Multiomic and Gene Editing (IMMERGE). European Commission. J.L. Sardina. (Josep Carreras Leukaemia Research Institute). 01/09/2023-31/08/2027. 3.309.969 €. Co-ordinator.
2 **Project**. Explotando la Edición CRISPR del Epigenoma para Descubrir Biomarcadores Moleculares que Predicen la Respuesta a los Epifármacos en Pacientes con Leucemia Mieloide. Ministerio de Ciencia e Innovación. Universidades. José L. Sardina Ortega. (Josep Carreras Leukaemia Research Institute). 01/05/2025-31/03/2027. 200.000 €.
3 **Project**. PID2019-111243RAI00, Descifrando el impacto de TET2 sobre la estructura de la cromatina en el inicio leucémico. Ministerio de Ciencia e Innovación. J.L. Sardina. (Josep Carreras Leukaemia Research Institute). 01/06/2020-31/05/2023. 145.200 €. Principal investigator.
4 **Project**. 20-0269, Uncovering the regulation of chromatin structure by TET2 during leukemic cell fate decisions. World Wide Cancer Research Foundation. JL. Sardina. (Josep Carreras Leukaemia Research Institute). 01/02/2020-01/02/2023. 216.500 €. Principal investigator.
5 **Project**. Dynamics of human genome architecture in stable and transient gene expression changes (4D-GENOME). European Research Council. Miguel Beato. (Centre for Genomic Regulation). 2014-2019. 12.000.000 €. Team member.
6 **Project**. SAF2015-68740-P, DNA hydroxymethylation and methylation dynamics during ultra-fast reprogramming of somatic cells. Ministerio de Economia y Competitividad. Graf Thomas. (Centro de Regulación Genómica). 01/01/2016-31/12/2018. 403.172 €. Co-ordinator.
7 **Project**. Genomic Instability. MINISTERIO DE EDUCACION Y CIENCIA. Andres Aguilera. (INSTITUTO DE BIOLOGIA FUNCIONAL Y GENOMICA). 2007-2011. 6.000.000 €.
8 **Project**. Estudio de la función y de la regulación de la expresión de PTP-Bas durante la diferenciación megacariocítica. MINISTERIO DE EDUCACION Y CIENCIA. Angel Hernandez Hernandez. (University of Salamanca). 01/10/2006-31/12/2009. 72.600 €.